HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief

This article was originally published in The Rose Sheet

Executive Summary

Rockline Industries recalls baby and personal wipes due to mold contamination; Symrise strengthens its position in West Africa with new Nigerian subsidiary; P&G’s operations are suspended in Argentina due to alleged tax evasion. More news in brief.

You may also be interested in...



Aussie Regulator ID’s Underpreserved Cosmetics As Adverse-Event Contributor

Australia’s Competition and Consumer Commission says that 30% of all consumer product injury reports it received in the past year were associated with cosmetics, which it partially attributes to inadequate product preservation. In addition to promoting good manufacturing practices, the ACCC will be surveying cosmetic product labeling on a continuing basis.

P&G Crest Whitestrips Patents Stand Up To ‘Indefiniteness’ Challenge

P&G prevails in U.S. district court arguing that three private-label tooth-whitening-strip firms infringed three of its patents for Crest Whitestrips. The defendants plan to appeal the ruling against their motion that two of P&G’s patents are invalid.

Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval

The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS019280

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel